Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × chiauranib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 4 Small Cell Lung Carcinoma 3 Ovarian Neoplasms 3 Lymphoma, Non-Hodgkin 2 Triple Negative Breast Neoplasms 1 Sarcoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Carcinoma, Hepatocellular 1

Interventions

Doxorubicin 120 Ifosfamide 70 Radiotherapy 65 Cyclophosphamide 61 Gemcitabine 53 Filgrastim 46 Trabectedin 36 pazopanib 34 Docetaxel 34 Etoposide 33 pembrolizumab 32 Vincristine 30 Cisplatin 29 Nivolumab 27 Irinotecan 21 Magnetic Resonance Spectroscopy 20 Carboplatin 20 Ipilimumab 19 Surgical Procedures, Operative 18 Radiation 18 Temozolomide 17 Mesna 16 Melphalan 16 Biopsy 16 Bevacizumab 16 Sirolimus 15 Granulocyte Colony-Stimulating Factor 15 Drug Therapy 15 Dactinomycin 15 Blood Specimen Collection 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05497843 2025-04-03

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Chipscreen Biosciences, Ltd.

Phase 2 Completed

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡